BioAge Announces First Cohort Dosed in Phase 1b Clinical Trial of Apelin Receptor Agonist BGE-105, Under Development for Muscle Aging Indications

RICHMOND, Calif.–(BUSINESS WIRE)–BioAge Labs, Inc., a biotechnology company developing therapies that target the molecular causes of aging to extend healthy human lifespan, today announced that the first cohort has been dosed in a trial of phase 1b of BGE-105, a highly selective and potent small molecule agonist of the apelin APJ receptor.

Apelin, the natural ligand of the APJ receptor, regulates multiple aspects of muscle metabolism, growth and repair. BioAge’s AI-driven discovery platform, based on the analysis of proprietary data from aging human cohorts, revealed that apelin protein levels decline with age and are strongly associated with longevity and to the preservation of muscle strength, identifying APJ as an attractive target for the treatment of clinical indications related to muscle aging. BGE-105 binds to APJ and mimics the activity of apelin.

“In aged mouse models, BGE-105 significantly rescued muscle atrophy due to limb immobilization, prevented loss of muscle function with age, and induced biomarkers of muscle regeneration,” said the BioAge advisor William Evans, PhD, adjunct professor at UC Berkeley and Duke. “We believe BGE-105 has the potential to prevent muscle atrophy and improve muscle function in the elderly.”

The primary objective of BioAge’s randomized, placebo-controlled study is to evaluate the safety and tolerability of BGE-105 in healthy adults. Up to 72 healthy adult volunteers, at least half of whom are over 50, will be enrolled. Several previous phase 1 trials conducted by Amgen found oral or intravenous BGE-105 to be safe and well tolerated in 190 subjects, with no associated serious adverse events reported.

In addition, the trial will characterize the pharmacokinetic (PK) and pharmacodynamic (PD) effects of BGE-105 and assess muscle parameters and relevant biomarkers as secondary endpoints.

“BGE-105 is a promising compound with the potential to address multiple serious indications related to muscle aging, from acute hospital indications to chronic diseases,” said Kristen Fortney, PhD, CEO of BioAge. “Following the completion of the Phase 1b trial, BioAge will proceed with a Phase 2 proof-of-concept trial of BGE-105 to improve recovery in patients with hospitalization-related muscle wasting, an acute indication with a high unmet medical need.”

In April 2021, BioAge entered into an exclusive worldwide licensing agreement with Amgen, Inc. to develop and commercialize BGE-105 to improve muscle aging https://www.businesswire.com/news/home/20220419005141/en/BioAge-Announces-First-Cohort-Dosed-in-Phase-1b-Clinical-Trial-of-the-Apelin-Receptor-Agonist-BGE-105-Under-Development-for-Muscle-Aging-Indications. The license covers all indications. BioAge is responsible for the development, manufacturing and marketing of BGE-105 worldwide.

About BioAge

BioAge is a clinical-stage biotechnology company developing a pipeline of treatments to extend healthy lifespan by targeting the molecular causes of aging. The company uses its discovery platform, which combines quantitative analysis of proprietary longitudinal human samples with detailed health records following individuals throughout their lives, to map key molecular pathways that impact human aging by good health, thereby revealing the causes of age-related diseases. By targeting the mechanisms of aging with a broad and mechanistically diverse drug portfolio, BioAge will unlock opportunities to treat or even prevent these diseases in entirely new ways. To date, BioAge has raised $127 million from Andreessen Horowitz, Kaiser Foundation Hospitals and others. BioAge currently has three clinical-stage programs in its growing portfolio. For more information about BioAge, visit the company’s website at https://www.bioagelabs.com.

About Michael Bill

Check Also

Putin doesn’t think invading Ukraine a ‘mistake’: Scholz | Russo-Ukrainian War

German Chancellor says there is no indication Putin has changed his stance on Ukraine as …